regimen for hepatitis C

AbbVie published the results of the first of six clinical trials Phase III, fully exploring oral, bezinterferonovy 12 -week treatment regimen for hepatitis C ; results demonstrate a 96- percent efficiency (SVR 12) in previously untreated patients with hepatitis C genotype

Published data confirm the results of Phase II clinical trials c comparable virologic response and tolerability
Today it is the largest clinical program investigating fully oral, bezinterferonovy regimen in patients with genotype 1
Terms of basic filing for registration – 2nd quarter 2014, according to the plan
About 160 million people worldwide are infected with chronic hepatitis C, most of them are virus genotype 1 . Continue reading